STOCK TITAN

Eli Lilly and Company (LLY) Stock News, Jun-Jul 2025

LLY NYSE

Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.

Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.

Rhea-AI Summary

Eli Lilly (NYSE:LLY) has successfully completed its acquisition of Verve Therapeutics (NASDAQ:VERV), a Boston-based clinical-stage biotechnology company specializing in genetic medicines for cardiovascular disease. The strategic acquisition aims to revolutionize cardiovascular treatment through the development of one-time genetic therapies that could provide lifelong cardiovascular risk reduction.

Led by Ruth Gimeno, Lilly's group vice president of Diabetes and Metabolic Research and Development, this acquisition represents a significant step towards expanding Lilly's presence in the cardiovascular therapeutic space and advancing innovative genetic medicine solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.90%
Tags
-
Rhea-AI Summary

Eli Lilly (NYSE:LLY) has received a positive opinion from the European Medicines Agency's CHMP for donanemab, its treatment for early symptomatic Alzheimer's disease. The recommendation specifically targets adults with confirmed amyloid pathology who are ApoE4 heterozygotes or non-carriers.

The positive opinion was supported by data from the TRAILBLAZER-ALZ 2 and TRAILBLAZER-ALZ 6 clinical trials. The trials demonstrated significant slowing of cognitive decline and reduced disease progression risk. The modified dosing schedule in TRAILBLAZER-ALZ 6 showed lower incidence of ARIA-E while maintaining efficacy.

With 6.9 million Europeans affected by Alzheimer's disease, and this number expected to double by 2050, the European Commission's final regulatory decision is anticipated in the coming months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.90%
Tags
none
-
Rhea-AI Summary

Eli Lilly (NYSE:LLY) has scheduled its second-quarter 2025 financial results announcement for August 7, 2025. The company will host a conference call at 8:30 a.m. Eastern time to discuss the quarterly performance with investors, media, and the general public.

The event will be accessible through a live webcast via Lilly's investor relations website, with a replay available after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
conferences earnings
Rhea-AI Summary

Eli Lilly (NYSE: LLY) has successfully completed its tender offer for Verve Therapeutics (NASDAQ: VERV). The offer, which expired on July 23, 2025, consisted of $10.50 per share in cash plus one non-tradable contingent value right (CVR) worth up to $3.00 per share upon achieving specific milestones.

The tender offer saw 49,882,464 shares validly tendered, representing approximately 55.7% of Verve's outstanding shares. All conditions of the offer have been met, and Lilly will promptly pay for all validly tendered shares. The acquisition is expected to be finalized on July 25, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
-
Rhea-AI Summary

Eli Lilly (NYSE:LLY) has received FDA approval for an updated label with a new dosing schedule for Kisunla (donanemab-azbt), its monthly Alzheimer's treatment. The modified titration schedule demonstrated a 41% reduction in ARIA-E incidents at 24 weeks and 35% reduction at 52 weeks compared to the original dosing.

The new dosing maintains Kisunla's efficacy while improving safety, achieving similar amyloid plaque removal (67% reduction vs. 69% originally) and P-tau217 reduction. The treatment, initially approved in July 2024, has shown to slow cognitive decline by up to 35% in less advanced patients and 22% in the overall population.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
-
Rhea-AI Summary
Eli Lilly (NYSE: LLY) has announced its quarterly dividend payment for Q3 2025. The company's board of directors has declared a dividend of $1.50 per share on outstanding common stock. Shareholders who are on record as of August 15, 2025, will receive the dividend payment on September 10, 2025. This dividend declaration demonstrates Lilly's commitment to providing regular returns to its shareholders through dividend distributions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
dividends
Rhea-AI Summary
Eli Lilly announced positive Phase 3 trial results for efsitora alfa, a novel once-weekly insulin treatment for type 2 diabetes. The QWINT-1, QWINT-3, and QWINT-4 trials demonstrated that efsitora met primary endpoints for A1C reduction compared to daily basal insulin. In QWINT-1, efsitora reduced A1C by 1.31% vs 1.27% for insulin glargine at 52 weeks. QWINT-3 showed 0.86% reduction vs 0.75% for insulin degludec, while QWINT-4 achieved 1.07% reduction matching insulin glargine. The drug's safety profile was comparable to common daily basal insulins, with QWINT-1 showing 40% fewer hypoglycemic events. Notably, efsitora's once-weekly dosing could eliminate over 300 injections annually. Lilly plans to submit efsitora for regulatory approval by year-end.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
-
Rhea-AI Summary
Eli Lilly announced positive Phase 3 ACHIEVE-1 trial results for orforglipron, their first-in-class oral GLP-1 receptor agonist for type 2 diabetes. The once-daily pill demonstrated significant A1C reductions of 1.3% to 1.6% from baseline across doses (3mg, 12mg, 36mg) at 40 weeks. The highest dose achieved notable weight loss of 16.0 lbs (7.9%). Up to 76.2% of participants reached target A1C levels <7%. The drug showed early efficacy within four weeks and maintained a safety profile consistent with injectable GLP-1s, with mainly gastrointestinal side effects. Importantly, orforglipron requires no food or water restrictions, potentially offering a convenient alternative to injectable treatments. Lilly plans regulatory submissions for weight management in 2025 and type 2 diabetes in 2026, with additional trial results expected later this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
-
Rhea-AI Summary
Eli Lilly (NYSE: LLY) has announced a definitive agreement to acquire Verve Therapeutics (Nasdaq: VERV), a clinical-stage biotech company specializing in genetic medicines for cardiovascular disease. The deal values Verve at $10.50 per share in cash ($1.0 billion), plus a CVR worth up to $3.00 per share, potentially reaching $13.50 per share ($1.3 billion total). Verve's lead program, VERVE-102, is a first-in-class in vivo gene editing treatment targeting PCSK9 for cardiovascular disease, designed as a one-time treatment for conditions like heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. The FDA has granted Fast Track designation to VERVE-102, currently in Phase 1b trials. The acquisition price represents a 113% premium to Verve's 30-day volume-weighted average trading price, with the deal expected to close in Q3 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
Rhea-AI Summary
Eli Lilly (NYSE: LLY) announced that Zepbound's highest approved doses (12.5 mg and 15 mg) will be available in single-dose vials for $499/month through LillyDirect's Self Pay Pharmacy Solutions starting July 7, 2025. All Zepbound doses will now be accessible at $499/month or less ($349 for starter dose), regardless of insurance status. In clinical trials, adults taking Zepbound 15 mg achieved remarkable results, with average weight loss of 48 lbs (~21%) and approximately one-third losing over 58 lbs (25%). The complete range includes 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses, with pricing through the Self Pay Journey Program ranging from $349-$1,049, but capped at $499 with program benefits. The medication is indicated for adults with obesity or overweight with weight-related conditions and has shown significant efficacy in both diabetic and non-diabetic populations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
none

FAQ

What is the current stock price of Eli Lilly (LLY)?

Eli Lilly (LLY) last closed at $1,347.11.

What is the market cap of Eli Lilly (LLY)?

The market cap of Eli Lilly (LLY) is approximately $1.2T.